Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.33-
QQQ
716.250.03%
BTC/USD
77628.270.2707%
DIA
535.550.09%
GLD
409.230.08%
TLT
82.940.07%

Capricor Therapeutics Inc

CAPRNASDAQ
Trade with Public
Trade with Public
$9.59
-0.47-4.67%
At close: Aug 28, 5:00 PM EST
$9.59
0.00190.02%
After Hours: 7:55 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Capricor Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Capricor Therapeutics (CAPR).

Price Target Range — 12 Quarters

Analyst Consensus — 9 Analysts

6Buy
3Hold
Consensus RatingBuy# Analysts9Avg. Consensus PT$34Upside to Avg. PT+250.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 14, 2026Cantor FitzgeraldKristen KluskaUpgradeNeutral→Overweight$4→$28
Jul 31, 2026Jones TradingCatherine NovackDowngradeBuy→Hold—
More with Benzinga EdgeGet Access

Analyst Ratings News

This Capricor Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Wall Street analysts revised their ratings for top stocks. Visit benzinga.com/analyst-stock-ratings for all changes, including upgrades and downgrades.
Avi Kapoor

PRO
Cantor Fitzgerald Upgrades Capricor Therapeutics to Overweight, Raises Price Target to $28

Cantor Fitzgerald analyst Kristen Kluska upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Overweight and raises the price target from $3.5 to $28.
Benzinga Newsdesk

PRO
Piper Sandler Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $2

Piper Sandler analyst Edward Tenthoff downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $58 to $2.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $3.5

Cantor Fitzgerald analyst Kristen Kluska downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $62 to $3.5.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Downgrades Capricor Therapeutics to Neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Capricor Therapeutics (NASDAQ:CAPR) from Buy to Neutral.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $60 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:CAPR) with a Buy and maintains $60 price target.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved